Hugel America, Inc. announced that it expects to receive KRW 50.1075861 billion in funding from Hugel, Inc.
March 09, 2023
Share
Hugel America Inc. announced a private placement of 30,000 shares for a gross proceeds of KRW 50,107,586,100 on March 9, 2023. The transaction will include participation from returning investor, Hugel, Inc. The company issued shares through cash acquisition method. The transaction is expected to close April 30, 2023.
The transaction has been approved by the board of directors of the company.
Hugel Inc is a Korea-based company mainly engaged in the manufacture of biopharmaceuticals. The Company's product portfolio consists of botulinum toxins which used for treatment of benign essential blepharospasm and temporary improvement of moderate to severe glabellar lines including 50 unit types, 100 unit types and 200unit types; hyaluronic acid (HA) fillers which used for temporary removal of facial wrinkles including the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A and the chaeum VOLUS 20A; wellages, blue roses and other cosmetics. The Company sells its products in domestic and overseas markets.